Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

66.95USD
10:33am EST
Change (% chg)

$-1.20 (-1.76%)
Prev Close
$68.15
Open
$69.22
Day's High
$69.85
Day's Low
$66.87
Volume
669,870
Avg. Vol
2,410,830
52-wk High
$89.53
52-wk Low
$64.27

Select another date:
Photo

Gilead Sciences snares Roche veteran O'Day as CEO

Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum.

UPDATE 4-Gilead Sciences snares Roche veteran O'Day as CEO

* William Anderson to replace O'Day as Roche Pharmaceuticals CEO

Gilead Sciences to hire Roche executive O'Day as new CEO -source

Dec 9 Drugmaker Gilead Sciences Inc will name Roche Holding AG executive Daniel O'Day as its new chief executive officer, according to a source familiar with the matter.

BRIEF-Gilead Sciences Plans To Hire Daniel O'Day As Its Next CEO - WSJ

* DRUGMAKER GILEAD SCIENCES PLANS TO HIRE DANIEL O'DAY AS ITS NEXT CEO - WSJ, CITING SOURCES Source text : https://on.wsj.com/2C1oCCN Further company coverage:

High-cost Gilead cell therapy proves durable for some lymphoma patients

(This December 2 story corrects spelling in paragraph 5 to Alvarnas from Alvarnaz)

CORRECTED-UPDATE 1-High-cost Gilead cell therapy proves durable for some lymphoma patients

SAN DIEGO, Dec 2 Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday.

At 2 years, Gilead lymphoma therapy active in 40 pct of patients

SAN DIEGO, Dec 2 Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta continued to respond to the cell therapy after at least two years of follow up, the company said on Sunday.

Roche buys U.S. biotech Jecure in race for liver disease drugs

ZURICH Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.

Roche buys U.S. biotech Jecure in race for liver disease drugs

ZURICH, Nov 27 Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.

Gilead 3rd quarter profit falls as hepatitis C drug sales wane

Third quarter sales of Gilead Sciences Inc's flagship hepatitis C drugs fell by more than half as competition increased, sending net profit down 22 percent from a year earlier, the U.S. biotechnology company said on Thursday.

Select another date: